NCT04821622
Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC
Associated Conditions
Prostate CancerSponsor
Pfizer Inc.
This study will explore the safety and the efficacy (how well it works) of an investigational drug talazoparib, when added to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC).
This study is currently enrolling.